Consistent with these findings, the BIRC2,3,4 inhibitor AZD5582 significantly reduced vitality and/or caused cell death selectively in 11q21.2 amplified FA-HNSCC cells, with no negative effect on the viability of normal cells or FA-HNSCC. Here, BIRC2 is linked to head and neck squamous cell carcinoma.